Literature DB >> 14744748

Ataxia-telangiectasia-mutated (ATM) gene in head and neck squamous cell carcinoma: promoter hypermethylation with clinical correlation in 100 cases.

Lingbao Ai1, Quynh N Vo, Chunlai Zuo, Liwen Li, Wenhua Ling, James Y Suen, Ehab Hanna, Kevin D Brown, Chun-Yang Fan.   

Abstract

The Ataxia-telangiectasia-mutated (ATM) gene product is a well-characterized tumor suppressor that plays a key role in maintenance of genomic stability. We have recently documented that the ATM promoter is a target for epigenetic silencing in cultured tumor cells. Here we show that aberrant methylation of the ATM promoter occurs in a significant percentage (25%) of head and neck squamous cell carcinomas. The presence of methylated ATM promoter shows a statistically significant correlation with an earlier age of initial diagnosis and decreased overall survival, particularly in early-stage tumors. These findings indicate that ATM promoter hypermethylation occurs in head and neck squamous cell carcinoma, and this feature is a potentially useful prognostic marker in this tumor type.

Entities:  

Mesh:

Year:  2004        PMID: 14744748     DOI: 10.1158/1055-9965.epi-082-3

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  34 in total

Review 1.  Epigenetic changes of DNA repair genes in cancer.

Authors:  Christoph Lahtz; Gerd P Pfeifer
Journal:  J Mol Cell Biol       Date:  2011-02       Impact factor: 6.216

2.  Linking ATM Promoter Methylation to Cell Cycle Protein Expression in Brain Tumor Patients: Cellular Molecular Triangle Correlation in ATM Territory.

Authors:  P Mehdipour; F Karami; Firouzeh Javan; M Mehrazin
Journal:  Mol Neurobiol       Date:  2014-08-27       Impact factor: 5.590

Review 3.  Targeting DNA repair in cancer: current state and novel approaches.

Authors:  Apostolos Klinakis; Dimitris Karagiannis; Theodoros Rampias
Journal:  Cell Mol Life Sci       Date:  2019-10-14       Impact factor: 9.261

Review 4.  DNA repair dysregulation from cancer driver to therapeutic target.

Authors:  Nicola J Curtin
Journal:  Nat Rev Cancer       Date:  2012-12       Impact factor: 60.716

5.  Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.

Authors:  Eiji Kubota; Christopher T Williamson; Ruiqiong Ye; Anifat Elegbede; Lars Peterson; Susan P Lees-Miller; D Gwyn Bebb
Journal:  Cell Cycle       Date:  2014-05-19       Impact factor: 4.534

6.  Alterations of ATM and CADM1 in chromosomal 11q22.3-23.2 region are associated with the development of invasive cervical carcinoma.

Authors:  Dipanjana Mazumder Indra; Sraboni Mitra; Anup Roy; Ranajit Kumar Mondal; Partha Sarathi Basu; Susanta Roychoudhury; Runu Chakravarty; Chinmay Kumar Panda
Journal:  Hum Genet       Date:  2011-06-05       Impact factor: 4.132

7.  ATM in oral carcinogenesis: association with clinicopathological features.

Authors:  Yuan He; Qianming Chen; Bingqi Li
Journal:  J Cancer Res Clin Oncol       Date:  2008-02-21       Impact factor: 4.553

Review 8.  Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer.

Authors:  N J Curtin
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

9.  Aberrant promoter methylation of multiple genes during pathogenesis of bladder cancer.

Authors:  Mariana Brait; Shahnaz Begum; André L Carvalho; Santanu Dasgupta; André L Vettore; Bogdan Czerniak; Otávia L Caballero; William H Westra; David Sidransky; Mohammad Obaidul Hoque
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-10       Impact factor: 4.254

10.  Recurrence in oral and pharyngeal cancer is associated with quantitative MGMT promoter methylation.

Authors:  Emanuela Taioli; Camille Ragin; Xiao-Hong Wang; Jiangying Chen; Scott M Langevin; Ashley R Brown; Susanne M Gollin; Seymour Garte; Robert W Sobol
Journal:  BMC Cancer       Date:  2009-10-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.